PRELUDE THERAPEUTICS INC (PRLD)

Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference

Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference

WILMINGTON, Del., May 09, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology...

PRLD Stock Earnings: Prelude Therapeutics Beats EPS for Q1 2024

PRLD stock results show that Prelude Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

First-in-class IV SMARCA2 degrader, PRT3789 and potentially best-in-class CDK9 inhibitor, PRT2527 remain on track to generate initial proof-of-concept data...

Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting

Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting

Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at...

Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting

Posters to highlight highly selective oral SMARCA2 degrader, potentially best-in-class CDK9 inhibitor and next-generation CDK4/6 inhibitor

Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting

Prelude Therapeutics to present preclinical data posters at the 2024 AACR on its oral SMARCA2 degrader, CDK9 inhibitor and next-gen CDK4/6 inhibitor...

Prelude Therapeutics to Participate in Barclays Global Healthcare Conference

Prelude Therapeutics to Participate in Barclays Global Healthcare Conference

Prelude Therapeutics' Kris Vaddi and Jane Huang to participate in fireside chat at Barclay's Global Healthcare conference 2024 on March 13 in Miami...

H.C. Wainwright cuts Prelude Therapeutics to neutral, cites valuation (NASDAQ:PRLD)

H.C. Wainwright has downgraded Prelude Therapeutics (PRLD) to neutral, citing valuation. The investment bank noted “investor anticipation” of initial results fr

Prelude Therapeutics files to sell 7.94M shares for holders (NASDAQ:PRLD)

Prelude Therapeutics files prospectus for proposed resale of 7.94M shares of common stock by selling stockholders. SEC filing.

Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024

Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024

First-in-class IV SMARCA2 degrader and potentially best-in-class CDK9 inhibitor on track to generate potential proof-of-concept data in 2024 Highly...

AI Meets Biotech: 3 Top Stocks Transforming Medical Science

The AI revolution is bringing big gains to biotechnology, including drugs, antibodies, and synthetic biology.

Prelude Therapeutics looks to raise $25M through a private placement (NASDAQ:PRLD)

Learn about Prelude Therapeutics' private placement to raise $25M, which will fund the advancement of its SMARCA2 portfolio and support general corporate...

Prelude Therapeutics Announces $25 Million Private Placement

Prelude Therapeutics Announces $25 Million Private Placement

WILMINGTON, Del., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage...

Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results

Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results

Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results ...

Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology

Multi-year collaboration to jointly discover, develop, and commercialize novel oncology medicines for up to five programs, with the first ADC program focusing on a SMARCA degrader

Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology

Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference

Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference

WILMINGTON, Del. and BOSTON, Oct. 14, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD), a clinical-stage precision...

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September

WILMINGTON, Del., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today...

Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Four lead programs on track to deliver clinical data and to inform future development plans Recent equity financing extends cash runway into...

Oversold Conditions For Prelude Therapeutics (PRLD)

Prelude Therapeutics To Participate in Jefferies Healthcare Conference

WILMINGTON, Del., May 31, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology...